» Articles » PMID: 33844184

Elevated Ambulatory Blood Pressure Measurements Are Associated with a Progressive Form of Fabry Disease

Overview
Date 2021 Apr 12
PMID 33844184
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Therefore, we have assessed blood pressure values and their possible correlations with clinical findings in a well described cohort of Fabry patients.

Methods: Between January 2015 and May 2019, all adult Fabry patients (n = 24 females, n = 8 males) referred to our institute were prospectively enrolled. During the first examination patient's genotype and clinical characteristics were recorded. Blood pressure data were obtained by standard observed office measurements followed, within 6 months, by ambulatory blood pressure monitoring and home self-recordings. Organ involvement, including kidneys, heart and brain, was monitored over time. Consequently, patients were defined as clinically stable or progressive through the Fabry Stabilization Index.

Results: The standard office measurements have diagnosed hypertension in three (9.37%) patients, but the ambulatory monitoring showed elevated blood pressure in six (18.75%) patients, revealing three cases of masked hypertension. All the hypertensive patients were females and, compared with normotensive subjects, they presented a lower glomerular filtration rate (p < 0.05) and a more advanced cardiac hypertrophy (p < 0.05). Four (66.7%) of them were diagnosed with a progressive form of the disease through the Fabry Stabilization Index while the majority of the normotensive group (84.6%, n = 19) was stable over time. No correlation was found between the prevalence of hypertension and the type of mutations causing Fabry disease.

Conclusion: Hypertension can be found in a restricted portion of clinically stable Fabry patients. In contrast, patients presenting with a progressive organ involvement, particularly renal impairment, have a major risk of developing uncontrolled blood pressure, and should be followed carefully. Moreover, the ambulatory blood pressure monitoring proved to be useful to reveal masked hypertension, which can contribute to the progressive worsening of the organ damage. Therefore, a proper diagnosis and therapy of hypertension may improve the outcome of Fabry patients.

Citing Articles

Management of Hypertension in Fabry Disease.

Kim S, Choi S Electrolyte Blood Press. 2023; 21(1):8-17.

PMID: 37434805 PMC: 10329903. DOI: 10.5049/EBP.2023.21.1.8.


Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies.

Averbuch T, White J, Fine N Front Cardiovasc Med. 2023; 10:1152568.

PMID: 37332587 PMC: 10272370. DOI: 10.3389/fcvm.2023.1152568.


The Many Faces of Arterial Hypertension in Hypertrophic Cardiomyopathy and Its Phenocopies: Bystander, Consequence, Modifier.

Tini G, Autore C, Musumeci B High Blood Press Cardiovasc Prev. 2021; 28(4):327-329.

PMID: 33905095 DOI: 10.1007/s40292-021-00458-6.

References
1.
Germain D, Brand E, Burlina A, Cecchi F, Garman S, Kempf J . Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Mol Genet Genomic Med. 2018; . PMC: 6081232. DOI: 10.1002/mgg3.389. View

2.
Alroy J, Sabnis S, Kopp J . Renal pathology in Fabry disease. J Am Soc Nephrol. 2002; 13 Suppl 2:S134-8. View

3.
Judd E, Calhoun D . Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015; 22(2):116-22. PMC: 4445132. DOI: 10.1053/j.ackd.2014.12.001. View

4.
Ortiz A, Oliveira J, Waldek S, Warnock D, Cianciaruso B, Wanner C . Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008; 23(5):1600-7. DOI: 10.1093/ndt/gfm848. View

5.
Germain D . Fabry disease. Orphanet J Rare Dis. 2010; 5:30. PMC: 3009617. DOI: 10.1186/1750-1172-5-30. View